Literature DB >> 3251164

Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis.

Y Oiso1, Y Iwasaki, K Kondo, K Takatsuki, A Tomita.   

Abstract

The effect of U50488H, a potent opioid kappa-receptor agonist, was investigated on the urine volume and on the secretion of arginine vasopressin (AVP) in response to dehydration or hyperosmolar or hypovolemic stimulation in conscious rats. This agonist markedly increased the urine volume in normally hydrated rats and suppressed plasma AVP in a dose-dependent manner in rats given hyperosmolar saline. This suppression of plasma AVP was completely reversed by concurrent injection of naloxone. U50488H also inhibited the release of AVP in dehydrated or hypovolemic rats. These findings indicate that the diuresis induced by U50488H is mainly caused by the suppression of plasma AVP. They also suggest that the kappa-opioid receptor plays an important role in regulating the secretion of AVP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3251164     DOI: 10.1159/000125078

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

1.  Differential modulation of N-type calcium channels by micro-opioid receptors in oxytocinergic versus vasopressinergic neurohypophysial terminals.

Authors:  Sonia I Ortiz-Miranda; Govindan Dayanithi; Cristina Velázquez-Marrero; Edward E Custer; Steven N Treistman; José R Lemos
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

Authors:  H J Kramer; W Uhl; B Ladstetter; A Bäcker
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

3.  Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Authors:  Jacob K Meariman; Jane C Sutphen; Juan Gao; Daniel R Kapusta
Journal:  Hypertension       Date:  2021-12-02       Impact factor: 10.190

4.  Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.

Authors:  M C H Ko; K J Willmont; H Lee; G S Flory; J H Woods
Journal:  Brain Res       Date:  2003-08-22       Impact factor: 3.252

5.  Effects of the selective kappa-opioid agonist U50,488 upon the electrical activity of supraoptic neurones in morphine-tolerant and morphine-naive rats.

Authors:  K M Pumford; J A Russell; G Leng
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

6.  Opioid antagonist diprenorphine microinjected into parabrachial nucleus selectively inhibits vasopressin response to hypovolemic stimuli in the rat.

Authors:  Y Iwasaki; M B Gaskill; R Fu; C B Saper; G L Robertson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 7.  The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms.

Authors:  Arpád Dobolyi; Miklós Palkovits; Ted B Usdin
Journal:  Prog Neurobiol       Date:  2009-10-24       Impact factor: 11.685

8.  A series of novel, highly potent and selective agonists for the kappa-opioid receptor.

Authors:  A G Hayes; P J Birch; N J Hayward; M J Sheehan; H Rogers; M B Tyers; D B Judd; D I Scopes; A Naylor
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

9.  Renal responses produced by microinjection of the kappa opioid receptor agonist, U50-488H, into sites within the rat lamina terminalis.

Authors:  Cynthia Franklin; Lourdes Fortepiani; Tin Nguyen; Yolanda Rangel; Randy Strong; Helmut B Gottlieb
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

10.  κ Opioid Receptor Agonist Inhibits Myocardial Injury in Heart Failure Rats through Activating Nrf2/HO-1 Pathway and Regulating Ca2+-SERCA2a.

Authors:  Tengfei Wu; Hui Yao; Binghua Zhang; Shenglai Zhou; Ping Hou; Keyan Chen
Journal:  Oxid Med Cell Longev       Date:  2021-07-30       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.